Shalby Ltd
Stock Snapshot
Price Performance
Vista Outlook
Basis of our Recommendation
Shalby Ltd is navigating a pivotal transition from a specialized orthopedic provider to a comprehensive multi-specialty healthcare entity. Management's focus on scaling its high-margin MedTech implant business and expanding into high-acuity care is crucial for driving revenue growth and enhancing margins. Recent strategic rationalizations, including the closure of underperforming units, reflect a disciplined approach to capital allocation, which Vista believes will support operational leverage and cash flow optimization. Despite facing short-term margin pressures due to expansion costs and geopolitical challenges affecting international patient volumes, the company's strong brand equity and the growing domestic healthcare market provide a solid foundation for future growth. Vista's financial outlook anticipates stable revenue growth and margins, with a target price reflecting a 38.77% expected upside. The healthcare sector's overall growth trajectory, supported by rising insurance coverage and demand for organized care, further bolsters Shalby's position. Key opportunities include the scaling of the MedTech segment and the commissioning of new facilities, while watchpoints include execution risks in the MedTech business and ongoing margin pressures. Overall, Shalby is well-positioned for sustainable growth over the next 12-24 months
Why We Like This Stock
- Management's focus on scaling the high-margin MedTech implant business is expected to drive revenue growth
- The transition to a multi-specialty provider enhances Shalby's competitive position in a growing domestic healthcare market
- Operational leverage from improved occupancy rates and new facility openings is anticipated to stabilize margins
Things To Watch Out For
- Short-term margin pressures from expansion costs and geopolitical tensions may impact profitability
- Execution risks in the MedTech business could hinder anticipated growth and margin recovery
- Increased tax liabilities and slower-than-expected margin expansion are concerns reflected in analyst estimates
Key Parameters
Financial Snapshot
View Technicals Analysis →| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 934 | 1,087 | 1,141 | 1,193 | 1,330 |
| Profit Before Tax (Cr.) | 119 | 47 | 61 | 60 | 69 |
| PBT Margin | 12.7% | 4.3% | 5.3% | 5.0% | 5.2% |
| Net Profit (Cr.) | 64 | 1 | 23 | 45 | 45 |
| Earnings Per Share | 6.1 | 0.4 | 2.4 | 3.6 | 4.2 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| Elara Capital | ► Accumulate | 173 | 14-Aug-2026 |
Company Overview
Show Company Profile
Shalby Limited operates a chain of multi-specialty hospitals in India and internationally. The company operates through Healthcare Services and Manufacturing segments. It offers rheumatology, knee and hip joint replacement, spine surgery, Paediatric orthopedic and trauma, arthroscopy, and arthroplasty; cardiothoracic and vascular surgery, coronary angiography, angioplasty and stenting, and cardiology services; root canal treatment, dental implants, crowns bridges, dentures, orthodontic treatment, dental cosmetic, teeth whitening, pediatric dentistry, dental veneers, gum treatment, and laser dentistry; dermatology; emergency and general medicine; cochlear implants and balloon sinuplasty; gastroenterology, obesity surgery, and endoscopy and laparoscopy; intensive and critical care; nephrology, urology, kidney transplant, dialysis, and interventional nephrology; and general surgery comprising varicose, hernia, and piles surgery. The company also provides liver transplant; maxillofacial surgery; neurology, ideal stroke treatment, epilepsy, endovascular/interventional neurosurgery, and trans cranial doppler; obstetrics and gynaecology; surgical oncology, medical oncology, radiation oncology, bone marrow transplant, onco-psychology, onco-dietetics, onco-physiotherapy, and home care; ophthalmology; paediatrics; pathology and microbiology; psychiatry; pulmonology and chest; interventional and diagnostic radiology; and robotic joint replacement. The company was formerly known as Shalby Hospitals Limited and changed its name to Shalby Limited in February 2008. Shalby Limited was founded in 1994 and is based in Ahmedabad, India.